Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

被引：0
作者：
Satoshi Ikeda
Terufumi Kato
Takashi Ogura
Akimasa Sekine
Tsuneyuki Oda
Noriyuki Masuda
Satoshi Igawa
Ken Katono
Sakiko Otani
Kouzo Yamada
Haruhiro Saito
Tetsuro Kondo
Yukio Hosomi
Yoshiro Nakahara
Masanori Nishikawa
Keiko Utumi
Yuki Misumi
Takeharu Yamanaka
Kentaro Sakamaki
Hiroaki Okamoto
机构：
[1] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine
[2] Kanagawa Cancer Center,Department of Thoracic Oncology
[3] Kitasato University Hospital,Department of Respiratory Medicine
[4] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Division of Thoracic Oncology and Respiratory Medicine
[5] Fujisawa City Hospital,Department of Respiratory Medicine
[6] Ibaraki Prefectural Central Hospital,Department of Respiratory Medicine
[7] Yokohama Municipal Citizen’s Hospital,Department of Respiratory Medicine and Medical Oncology
[8] Yokohama City University School of Medicine,Department of Biostatistics
来源：
BMC Cancer | / 18卷
关键词：
Non-small cell lung cancer; Docetaxel; Bevacizumab; Circulating endothelial cell;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 200 条
[1]  
Schiller JH(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[2]  
Harrington D(1999)Taxol suppresses dynamics of individual microtubules in living human tumor cells Mol Biol Cell 10 947-959
[3]  
Belani CP(2005)Docetaxel: a review of its use in metastatic breast cancer Drugs 65 2513-2531
[4]  
Langer C(1998)The taxoids. Comparative clinical pharmacology and therapeutic potential Drugs 55 5-30
[5]  
Sandler A(1997)Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol Cancer Res 57 81-86
[6]  
Krook J(1996)The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1843-1849
[7]  
Yvon AM(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[8]  
Wadsworth P(2009)Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227-1234
[9]  
Jordan MA(2001)The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369-3372
[10]  
Lyseng-Williamson KA(2008)Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Cancer Cell 14 263-273
12345678910